This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Behranwala, K. A. Articles by Thomas, J. M. Search for Related Content PubMed PubMed Citation Articles by Behranwala, K. A. Articles by Thomas, J. M.

Prognosis of Lymph Node Metastasis in Soft Tissue Sarcoma

From the Sarcoma and Melanoma Unit, Royal Marsden NHS Trust, United Kingdom.

Correspondence: Address correspondence and reprint requests to: Kasim A. Behranwala, MS, DNB, FRCS (Ed), FRCS (Glas), Sarcoma and Melanoma Unit, Royal Marsden NHS Trust, 203 Fulham Road, London SW3 6JJ, UK; Fax: 44-0-20-7808-2673, E-mail: kbehranwala{at}hotmail.com

Background: We defined the tumor characteristics and prognosis of patients with regional lymph node metastasis (RLNM) from soft tissue sarcoma.

Methods: All patients with RLNM from soft tissue sarcoma were identified from the Royal Marsden Hospital Sarcoma Unit prospective database from January 1990.

Results: A total of 73 (3.4%) of 2127 patients had RLNM. Fifty-seven patients (78.1%) had RLNM as the first site of spread, and 16 patients (21.9%) presented with RLNM and distant metastasis synchronously. The most common histologies were rhabdomyosarcoma, epithelioid sarcoma, and angiosarcoma. There were 9 T1 and 36 T2 tumors, and tumor size was not available in 28 patients. There were 6 grade 1, 16 grade 2, and 51 grade 3 tumors. Forty-two patients presented with RLNM along with the primary tumor. Of the remaining patients, the median time to development of RLNM from diagnosis of the primary tumor was 13.5 months (95% confidence interval [CI], 1–100 months). The 1-year survival for patients with isolated RLNM was 77.49% (95% CI, 62.99%–86.88%), compared with 36.27% (95% CI, 13.32%–60.04%) for patients who presented with RLNM and distant metastasis (P = .005). The 1-year survival for metachronous and synchronous RLNM was 94.44% (95% CI, 66.64%–99.20%) and 67.54% (95% CI, 47.89%–81.12%), respectively (P = .05).

Conclusions: Lymph node metastasis is rare. Patients who present with isolated RLNM have an improved survival compared with patients who present with regional and distant metastasis at diagnosis. Synchronous RLNM with the primary tumor have a poorer outcome than metachronous RLNM in the absence of distant metastasis.

Key Words: Lymph node metastasis • Soft tissue sarcoma • Prognosis • Survival

This article has been cited by other articles:

				D. Kotilingam, D. C. Lev, A. J. F. Lazar, and R. E. Pollock Staging Soft Tissue Sarcoma: Evolution and Change CA Cancer J Clin, September 1, 2006; 56(5): 282 - 291. [Abstract] [Full Text] [PDF]

				C. Leowardi, U. Hinz, Y. Hormann, M. N. Wente, G. Mechtersheimer, F. Willeke, D. Bockler, H. Friess, J.-R. Allenberg, C. Herfarth, et al. Malignant Vascular Tumors: Clinical Presentation, Surgical Therapy, and Long-Term Prognosis Ann. Surg. Oncol., December 1, 2005; 12(12): 1090 - 1101. [Abstract] [Full Text] [PDF]

				M. A. Clark, C. Fisher, I. Judson, and J. M. Thomas Soft-Tissue Sarcomas in Adults N. Engl. J. Med., August 18, 2005; 353(7): 701 - 711. [Full Text] [PDF]